| [1] |
Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China[J]. Cancer Commun (Lond), 2022, 42(10): 937-970.
|
| [2] |
Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer[J]. Lancet, 2021, 398(10299): 535-554.
|
| [3] |
Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy[J]. J Hematol Oncol, 2019, 12(1): 134.
|
| [4] |
Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020, 37(4): 443-455.
|
| [5] |
Wang S, Fu JL, Hao HF, et al. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy[J]. Pharmacol Res, 2021, 170: 105728.
|
| [6] |
Lin CL, Yu CI, Lee TH, et al. Plumbagin induces the apoptosis of drug-resistant oral cancer in vitro and in vivo through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction[J]. Phytomedicine, 2023, 111: 154655.
|
| [7] |
Chen Y, Zhao C, Liu X, et al. Plumbagin ameliorates liver fibrosis via a ROS-mediated NF-small ka, CyrillicB signaling pathway in vitro and in vivo[J]. Biomed Pharmacother, 2019, 116: 108923.
|
| [8] |
Kong X, Luo J, Xu T, et al. Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi-1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP[J]. Oncol Rep, 2017, 37(6): 3423-3432.
|
| [9] |
Jiang ZB, Xu C, Wang W, et al. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8(+) T cells [J]. Pharmacol Res, 2021, 169: 105656.
|
| [10] |
Leader AM, Grout JA, Maier BB, et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J]. Cancer Cell, 2021, 39(12): 1594-1609 e12.
|
| [11] |
Wang XR, Jiang ZB, Xu C, et al. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response[J]. Pharmacol Res, 2022, 179: 106198.
|
| [12] |
Xu C, Jiang ZB, Shao L, et al. beta-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer[J]. Pharmacol Res, 2023, 191: 106739.
|
| [13] |
Yao L, Yan D, Jiang B, et al. Plumbagin is a novel GPX4 protein degrader that induces apoptosis in hepatocellular carcinoma cells[J]. Free Radic Biol Med, 2023, 203: 1-10.
|
| [14] |
Zhang R, Wang Z, You W, et al. Suppressive effects of plumbagin on the growth of human bladder cancer cells via PI3K/AKT/mTOR signaling pathways and EMT[J]. Cancer Cell Int, 2020, 20: 520.
|
| [15] |
Sakunrangsit N, Ketchart W. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/beta-catenin pathway in endocrine resistant breast cancer[J]. Pharmacol Res, 2019, 150: 104517.
|
| [16] |
Li T, Lv M, Chen X, et al. Plumbagin inhibits proliferation and induces apoptosis of hepatocellular carcinoma by downregulating the expression of SIVA[J]. Drug Des Devel Ther, 2019, 13:1289-1300.
|
| [17] |
Kajarabille N, Latuned-Data GO. Programmed cell-death by ferroptosis: antioxidants as mitigators [J]. Int J Mol Sci, 2019, 20(19):4968.
|
| [18] |
Hu Q, Zhu W, Du J, et al. A GPX4-targeted photosensitizer to reverse hypoxia-induced inhibition of ferroptosis for non-small cell lung cancer therapy[J]. Chem Sci, 2023, 14(34): 9095-9100.
|
| [19] |
Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 108.
|
| [20] |
Li YC, He SM, He ZX, et al. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells[J]. Cancer Lett, 2014, 344(2): 239-259.
|